PART I Item 1. Busines s Overview We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead p...
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001778922-26-000020 | EDGAR | 129K words |
No 10-Q filings indexed.
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001778922-26-000018 | EDGAR | 3K words |
| 2026-03-09 | 0001778922-26-000004 | EDGAR | — |
| 2026-02-13 | 0001628280-26-008073 | EDGAR | — |
| 2026-02-09 | 0001628280-26-006460 | EDGAR | — |
7 total filings indexed. 2 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001778922 |
| Ticker | SGP |
| Exchange | Nasdaq |
| SIC | 3841: Surgical & Medical Instruments & Apparatus |
| Incorporated | DE |
| Website | https://www.spyglasspharma.com |
| Listed | 2026-02-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report